Sewell hosts World Pancreatic Cancer Day roundtable discussion

Participants discussed a newly approved treatment for advanced pancreatic cancer, a Medicare pathway for early detection tests and the need for sustained federal research funding.

Pancreatic Cancer Roundtable
U.S. Rep. Terri Sewell and participants in her World Pancreatic Cancer Day roundtable.Courtesy of Rep. Sewell's Office

U.S. Representative Terri Sewell, D-Alabama, Thursday convened lawmakers, researchers, advocates, industry experts and a pancreatic cancer survivor for a roundtable discussion on Capitol Hill marking World Pancreatic Cancer Day and highlighting groundbreaking advances in pancreatic cancer detection and treatment. The discussion focused on the historic progress made in 2026, the importance of sustained federal investment in cancer research, and the work still needed to improve outcomes for patients and families.

“2026 has shown us what is possible when we invest in groundbreaking research, embrace medical innovation, and work together to put patients first,” Sewell said. “From the FDA’s approval of a promising new targeted treatment to the enactment of our Nancy Gardner Sewell MCED Act, we are making meaningful progress in the fight against cancer. But we cannot afford to let up now. I will continue fighting to increase federal investments in pancreatic cancer research and ensure that patients and families have access to the breakthroughs that can save lives. Our goal must be to make early detection more accessible, expand treatment options, and turn today’s progress into tomorrow’s cures.”

The roundtable featured Julie Fleshman, JD, MBA, president and CEO of the Pancreatic Cancer Action Network, PanCAN; Brian Wolpin, MD, MPH, of Dana-Farber Cancer Institute and Harvard Medical School; Don Frost, PharmD, MBA, senior director of Payer and Health Systems Liaison at Revolution Medicines; and Joe Damore, a pancreatic cancer survivor.

“This year has marked a landmark moment in the fight against pancreatic cancer,” Sewell’s press release said. In August, the Food and Drug Administration approved RASONQUE (daraxonrasib), the first broad RAS-targeted treatment for metastatic pancreatic cancer. The groundbreaking therapy represents a major step forward for patients with advanced disease, offering a new treatment option against a cancer that has historically been extremely difficult to treat.

The year also brought “a historic victory for early cancer detection” with the enactment of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection, or MCED, Screening Coverage Act, bipartisan legislation led by Sewell and signed into law in February. The law establishes a pathway for Medicare coverage of qualifying multi-cancer early detection tests once FDA approved, helping ensure that seniors can benefit from emerging technologies capable of detecting multiple cancers through a single screening test.

“On World Pancreatic Cancer Day, we celebrate an extraordinary year of progress for pancreatic cancer patients with breakthroughs in research that were once thought impossible, but we know more work is needed,” said Julie Fleshman, JD, MBA, president and CEO of PanCAN. “Thanks to the leadership of Representative Sewell and the continued federal investment in pancreatic cancer research, advances are bringing new hope to patients and families. We must build on this momentum by continuing to increase the federal investment in cancer research to ensure the next generation of breakthroughs reaches patients who need them and survival becomes the expectation, not the exception.”

Sewell has also made increasing federal investment in pancreatic cancer research a priority. Earlier this year, she successfully led the effort to restore and increase appropriations for pancreatic cancer research through in the Congressionally Directed Medical Research Program in the fiscal year 2026 defense bill after funding for the program was completely eliminated in fiscal year 2025 under Republicans’ continuing resolution. Sewell secured a historic $20 million for the program, a $5 million increase from fiscal year 2024 funding levels. Building on that achievement, she secured an additional $25 million in the House-passed fiscal year 2027 defense appropriations bill.

Pancreatic cancer remains among the deadliest forms of cancer, in large part because it is often diagnosed at an advanced stage when treatment options are limited. According to Sewell, Thursday’s roundtable underscored the importance of continued collaboration among researchers, medical professionals, advocates, industry leaders, policymakers and survivors to accelerate scientific discovery and ensure that promising advances reach the patients who need them most.